Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Nick Beije,Jan Kraan,Walter Taal,B. van der Holt,H. M. Oosterkamp,Annemiek Walenkamp,Laurens V. Beerepoot,M. Hanse,M. E. van Linde,A. Otten,Rene Vernhout,F.Y.F.L. de Vos,Jan W. Gratama,Stefan Sleijfer,M. J. van den Bent

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

2015

Nick Beije
Jan Kraan
Walter Taal
B. van der Holt
H. M. Oosterkamp
Annemiek Walenkamp
Laurens V. Beerepoot
M. Hanse
M. E. van Linde
A. Otten
Rene Vernhout
F.Y.F.L. de Vos
Jan W. Gratama
Stefan Sleijfer
M. J. van den Bent

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

Keywords:

Bevacizumab
Medicine
Glioblastoma
Prospective cohort study
Randomized controlled trial
GPI-Linked Proteins
Pathology
Lomustine
Angiogenesis
Oncology
Internal medicine
Chemotherapy
Monoclonal
single agent

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations